Fan Zhang, Ph.D currently serves as the Search and Evaluation Lead, Worldwide Business Development at Pfizer with focus on Hematological Malignancies and Immune Cell Engagers Programs, Cell Tx. His notable transactions include leading the end-to-end acquisition of Trillium Therapeutics, equity investment of Oric Pharma, CaribouBIO, CellCentric, ImagoBio, Nextcure (served as board observer), clinical partnership with Roche/Genentech, BMS, Morphosys, Incyte. He also led the global product development team for Bavencio (avelumab) in lung cancer and hematological malignancy, subcutaneous formulation when he joined Pfizer in 2015.

He was at Novartis between 2005-15 in numerous roles ranging from Global Head of Operations for biomarker development, Global Program Senior Director/Global Program Head, Director of US Sales Management, Executive Director/Global Head for Oncology Life Cycle Management.

Before Novartis, Fan also served as the Global Brand Director for Campath (alemtuzumab) at Schering AG between 2001-04. Fan started his industry career at HMR/Aventis, first as the biopharmaceutical scientist, then progressed to project management/Associate Director.

Fan received his PhD from the University of Michigan in Clinical Pharmacology and B.S in Physical Chemistry from Peking University, respectively.

Outside of professional career, Fan has been involved in numerous professional/community organizations such as Bayhelix(member since 2005), Beachhelix co-leader and is the current President of Peking University Alumni Association, San Diego Chapter.

In addition, Fan is an avid Ironman distance triathlete/marathon runner, represented China at World Championship in Hawaii and became the first Chinese Ironman in 1995, competed at Asian Triathlon Continental Cup for China in 1998.